Introduction
Mycophenolate mofetil (MMF) is an immunosuppressive medication commonly used to prevent rejection in solid organ transplant recipients. Active metabolite of MMF, mycophenolic acid, inhibits inosine monophosphate dehydrogenase which is the rate-limiting enzyme in purine synthesis for T and B-cell proliferation [1] . Enterocytes are 50% dependent on the de novo pathway of purine synthesis which is why they are vulnerable to MMF's antimetabolic effects; this impedes the growth and replication of small bowel epithelial cells which leads to disruption of fluid absorption and diarrhea [2] . Injurious effects of MMF can be detected in the colon and include mucosal changes ranging from edema, erythema, erosions, and ulcerations. Histopathologic findings of MMF injury include crypt architectural distortion and crypt cell apoptosis [2] . The latency period between initiation of MMF exposure and onset of enterocolitis is between six months to 15 years with the average being around three years [3] .
Case Presentation
A 68-year-old male with a history of recurrent deep vein thrombosis on warfarin, single lung transplant secondary to idiopathic pulmonary fibrosis on MMF (1000 mg twice a day) for eight months prior to admission, diverticulitis and recurrent diverticular bleed complicated by sigmoidectomy and right colectomy with ileo-colonic anastomosis, respectively, presented with 6-8 episodes of maroon-colored stools daily for the past two months. Over this time, the patient had several admissions at different hospitals requiring blood transfusions and endoscopic evaluations. At an outside hospital, esophagogastroduodenoscopy (EGD) demonstrated esophageal, gastric, and duodenal ulcers. He was treated with oral mesalamine for presumed inflammatory bowel disease. The patient was referred to the hospital for a second opinion after his symptoms did not improve.
Physical examination was significant for a chronically ill-appearing man with mild tenderness in the right lower quadrant of the abdomen and maroon colored stools on digital rectal exam. The rest of the examination was unremarkable. Laboratory studies revealed a hemoglobin level of 9.4 g/dL (normal range, 13.5-17.5 g/dL), iron 36 ug/dL (normal range, 41-186 ug/dL), ferritin 134.5 ng/mL (normal range, 30 -565 ng/mL), and creatinine of 1.64 mg/dL (normal range, 0.73 -1.22 mg/dL). Electrolytes, liver function, blood cytomegalovirus DNA, stool for ova & parasites, interferon-gamma release assay, and stool Clostridium difficile antigen were negative. A magnetic resonance enterography (MRE) of the abdomen and pelvis demonstrated small bowel wall thickening, mural hyper-enhancement, and peri-enteric stranding involving a 10-cm segment of the distal terminal ileum extending to the ileo-colonic anastomosis (Figure 1 ). Biopsy of the ulcers with immunohistochemical staining for cytomegalovirus was negative. Histology revealed mild crypt architectural distortion with crypt cell apoptosis from the ascending colonic ulcers and patchy active ileitis from the ileo-colonic anastamotic ulcerations ( Figure 3 ).
FIGURE 3: Photomicrograph from the colon biopsy showing architectural distortion with unevenly spaced lumen and crypts
Several damaged crypts (black arrows) are present, scattered throughout the colonic mucosa (hematoxylin and eosin (H&E), original magnification x100). Also present are apoptotic bodies (green arrows) suggestive of cellular injury and turnover (H&E, original magnification x100). There is no evidence of active inflammation or viral cytopathic effect.
In view of MMF exposure and histopathologic findings of crypt architectural distortion and crypt cell apoptosis, our patient was diagnosed with MMF-induced enterocolitis and MMF was promptly discontinued.
Seventy-two hours after discontinuation of MMF, the patient continued to experience bloody diarrhea requiring RBC transfusions. Intravenous (IV) Solumedrol 20 mg every eight hours was initiated with mild improvement in the frequency of diarrhea. After five days of IV Solumedrol therapy, a repeat colonoscopy demonstrated evidence of complete healing of the numerous small ulcerations and improvement in the appearance of the large ulcerations, suggestive of overall endoscopic improvement ( Figure 4 ). The patient was transitioned to oral steroids and steadily experienced clinical improvement. Unfortunately, the patient's hospital stay was complicated by hypoxic respiratory failure and he succumbed to death from aspiration pneumonia.
Discussion
MMF is a commonly prescribed adjunct immunosuppressive agent in transplant therapy. Up to 45% of patients report diarrhea, vomiting, and abdominal pain; diarrhea being the most commonly reported side effect [4, 5] . As an immunosuppressant, MMF can affect the entire gastrointestinal system leading to clinical complications ranging from esophagitis, gastroesophageal reflux disease, to enteritis and colitis. Development of diarrhea due to enteritis and/or colitis can be difficult to recognize as only 2%-9% of patients on MMF develop these complications [5, 6] . Pathology can resemble inflammatory bowel disease, graft-versushost disease (GVHD), acute colitis or ischemia [6] . There are treatment differences for each condition which is why obtaining biopsies is recommended to differentiate between these etiologies [7] . Specific histologic features of MMF related colitis include: crypt architectural disarray, increased lamina propria inflammation, dilated damaged crypts, increased crypt epithelial apoptosis and GVHD-like changes [8] .
No guidelines are available to guide clinicians to treat MMF-induced enterocolitis. Several case reports have demonstrated that diarrhea improves within three to five days of discontinuing MMF [9] [10] . One systemic review revealed that in 98% of the cases, diarrhea resolves within 20 days upon discontinuation of the MMF [3] . If symptoms are persistent despite MMF discontinuation, prednisone and/or infliximab has shown improvement. Table 1 lists the cases of MMF induced colitis and how these patients were managed [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In 12 of the 13 case reports found, patient's symptoms improved after lowering the offending agent dose or discontinuing the medication. Out of the 13, only two patients were already on steroids [13, 14] . Out of the 13 cases, six of them underwent repeat colonoscopy at different times from the intervention to assess for healing [14] [15] [16] [17] [18] [19] . Bouhbouh et al. gave a single infusion of 5 mg/kg of infliximab after previous futile attempts with MMF discontinuation, and 50 mg of prednisolone IV daily for two weeks [11] . Within three days, after a single infusion of infliximab, the stool frequency dropped significantly [11] . The mucosal injury from MMF is thought to be related to the formation of immunotoxicologic reactions in the bowel, increased mucosal inflammation, and decreased mucosal protection [20] . The decreased mucosal protection is hypothesized secondary to the upregulation of intracellular phosphatidylcholines, prominent membrane phospholipid that maintains gastrointestinal barrier function, leading to disruption in membrane phospholipids and subsequently decreased mucosal defense [20] . One of the postulated mechanisms for mucosal inflammation is that the byproduct, acyl gluconoride, causes local irritation of the epithelium which then stimulates mononuclear cells to release tumor necrosis factor (TNF)-α, subsequently impacting the development of mucosal inflammation [20] .
Conclusions
Since the advent of post-transplant immunosuppression therapy, MMF-induced enterocolitis is uncommon with debilitating complications; limited data is available in the literature regarding the approach to treatment. There continues to be unanswered questions as to why some patients' have refractory colitis, the benefits of oral or IV steroids, or biologic therapy (i.e. Infliximab), and the need for endoscopic reassessment for mucosal healing. With more cases being reported, we can better understand the natural course of the disease and help identify some of the answers. It is also prudent for physicians to inform the pathologist when a patient is on mycophenolate so the pathologist can be mindful of drug-induced colitis in the differential in addition to inflammatory bowel disease and GVHD.
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